These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Genetic engineering of the donor species to control hyperacute xenograft rejection. White DJ; Cozzi E; Langford G; Oglesby T; Wang MW; Wright L; Wallwork J Adv Nephrol Necker Hosp; 1995; 24():331-40. PubMed ID: 7572417 [No Abstract] [Full Text] [Related]
45. Expression and function of human CD59 and human CD55 in transgenic mice. Somerville C; van Denderen B; Adam B; Aminian A; Allison J; Pearse M; d'Apice A Transplant Proc; 1995 Dec; 27(6):3565-6. PubMed ID: 8540103 [No Abstract] [Full Text] [Related]
47. [The role of membrane glycoproteins CD46, CD55 and CD59 in protection of tumor cells against complement lysis]. Wojnicz D; Bar J; Jankowski S Postepy Hig Med Dosw; 2002; 56(5):603-16. PubMed ID: 12587428 [TBL] [Abstract][Full Text] [Related]
48. Complement and target cells belong to the same species after liver xenografting: protection from hyperacute rejection. Valdivia LA; Fung JJ; Demetris AJ; Celli S; Pan F; Tsugita M; Starzl TE Transplant Proc; 1994 Jun; 26(3):1255. PubMed ID: 7518123 [No Abstract] [Full Text] [Related]
49. [Complement in organ xenotransplantation]. Dalmasso AP Rev Clin Esp; 1996 Mar; 196 Spec No():44-51. PubMed ID: 9206808 [No Abstract] [Full Text] [Related]
50. Membrane-bound regulators of complement activation in uveal melanomas. CD46, CD55, and CD59 in uveal melanomas. Goslings WR; Blom DJ; de Waard-Siebinga I; van Beelen E; Claas FH; Jager MJ; Gorter A Invest Ophthalmol Vis Sci; 1996 Aug; 37(9):1884-91. PubMed ID: 8759358 [TBL] [Abstract][Full Text] [Related]
51. Development and analysis of transgenic pigs expressing the human complement regulatory protein CD59 and DAF. Byrne G; McCurry K; Martin M; Platt J; Logan J Transplant Proc; 1996 Apr; 28(2):759. PubMed ID: 8623385 [No Abstract] [Full Text] [Related]
53. Use of a novel CD11b/CD18 inhibitory agent in a C6-deficient rat to evaluate delayed xenograft rejection. Johnson E; Leventhal J; Dalmasso A; Goswitz J; Simone P; Chen S; Moyle M; Matas A Transplant Proc; 1996 Apr; 28(2):728. PubMed ID: 8623367 [No Abstract] [Full Text] [Related]
55. Kidneys derived from mice transgenic for human complement blockers are protected in an in vivo model of hyperacute rejection. Lazzeri M; Mora M; Mulder LC; Marsicano G; Marinucci G; Boschi M; Bruzzone P; Alfani D; Cortesini R; Rossini M J Urol; 1998 Apr; 159(4):1364-9. PubMed ID: 9507885 [TBL] [Abstract][Full Text] [Related]
58. Transplantation of organs between species. White DJ Int Arch Allergy Immunol; 1992; 98(1):1-5. PubMed ID: 1378038 [TBL] [Abstract][Full Text] [Related]
59. [Xenotransplantation]. White DJ; Calne RY Chirurg; 1996 Apr; 67(4):324-30. PubMed ID: 8646917 [TBL] [Abstract][Full Text] [Related]
60. [Complement inhibition: a new therapeutic modality?]. Porcel JM Med Clin (Barc); 1995 Nov; 105(18):700-2. PubMed ID: 8538252 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]